Literature DB >> 19712993

Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.

Hyun Ju Lee1, Xianhua Xu, Gheeyoung Choe, Doo Hyun Chung, Jeong-Wook Seo, Jae Ho Lee, Choon-Taek Lee, Sanghoon Jheon, Sook-Whan Sung, Jin-Haeng Chung.   

Abstract

Epidermal growth factor receptor (EGFR) overexpression in nonsmall cell lung carcinomas (NSCLC) is variable ranging from 19% to 89% and its prognostic value remains controversial. We tried to investigate (1) EGFR protein expression using four different antibodies, (2) the correlation between protein overexpression and EGFR gene amplification, and (3) the correlation between EGFR genetic status and clinicopathologic features in NSCLC. We examined EGFR protein expression using four different antibodies including Zymed EGFR kit (Clone 31G7), Dako EGFR pharmDx kit (Clone 2-18C9), Dako (Clone H11) and Novocastra (Clone EGFR 113) by immunohistochemical analysis. The protein overexpression was compared to gene amplification status by fluorescence in situ hybridization (FISH). EGFR protein overexpression was observed in 56% of tumors with Zymed EGFR kit, in 51% with Dako EGFR pharmDx kit, in 5% with Dako and in 18% with Novocastra (p=0.010). Both Zymed and Dako pharmDx kit were more sensitive than the Dako test (clone H11) and Novocastra clone EGFR 113. EGFR overexpression was more prominent in squamous cell carcinomas (SCC) than adenocarcinomas (ADC) (71% vs. 48%, p=0.001 with Zymed, 61% vs. 45%, p=0.011 with Dako pharmDx kit; respectively). EGFR FISH-positivity as represented by high polysomy and gene amplification was observed in 45% of the NSCLC patients. Protein expression levels significantly correlated with the gene copy number per tumor cell (p<0.001). Our data showed a higher percentage of positive cells detected by Zymed and Dako pharmDx tests. The EGFR protein overexpression rate varied from 4% to 72% according to different antibody clones and histologic types. EGFR protein expression detected by Zymed and Dako pharmDx was significantly associated with a high EGFR gene copy number. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712993     DOI: 10.1016/j.lungcan.2009.07.014

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  26 in total

Review 1.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

2.  Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.

Authors:  Fanny Burel-Vandenbos; Laurent Turchi; Maxime Benchetrit; Eric Fontas; Zoe Pedeutour; Valérie Rigau; Fabien Almairac; Damien Ambrosetti; Jean-François Michiels; Thierry Virolle
Journal:  Neuro Oncol       Date:  2013-08-09       Impact factor: 12.300

3.  Copy Number Alterations in Tumor Genomes Deleting Antineoplastic Drug Targets Partially Compensated by Complementary Amplifications.

Authors:  Ha Vu Tran; Alexandra K Kiemer; Volkhard Helms
Journal:  Cancer Genomics Proteomics       Date:  2018 Sep-Oct       Impact factor: 4.069

4.  Lung carcinoma progression and survival versus amino- and carboxyl-parathyroid hormone-related protein expression.

Authors:  Randolph H Hastings; Philippe R Montgrain; Rick A Quintana; Boris Chobrutskiy; Ashkhan Davani; Atsushi Miyanohara; Sepi Mahooti
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-25       Impact factor: 4.553

5.  Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma.

Authors:  Elisa Lappi-Blanco; Johanna M Mäkinen; Siri Lehtonen; Henna Karvonen; Raija Sormunen; Kirsi Laitakari; Shirley Johnson; Riitta Mäkitaro; Risto Bloigu; Riitta Kaarteenaho
Journal:  Tumour Biol       Date:  2016-08-01

6.  Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis.

Authors:  Evangelos Tsiambas; Nicholas S Mastronikolis; Alicia Y Lefas; Stavros N Georgiannos; Vasileios Ragos; Panagiotis P Fotiades; Nikolaos Tsoukalas; Nikolaos Kavantzas; Andreas Karameris; Dimitrios Peschos; Efstratios Patsouris; Konstantinos Syrigos
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

7.  Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Authors:  Stefanie Derer; Sven Berger; Martin Schlaeth; Tanja Schneider-Merck; Katja Klausz; Stefan Lohse; Marije B Overdijk; Michael Dechant; Christian Kellner; Iris Nagelmeier; Andreas H Scheel; Jeroen J Lammerts van Bueren; Jan G J van de Winkel; Paul W H I Parren; Matthias Peipp; Thomas Valerius
Journal:  Neoplasia       Date:  2012-03       Impact factor: 5.715

8.  Leser–Trélat syndrome in malignant mesothelioma and pulmonary adenocarcinoma: is the EGFR pathway part of the syndrome?

Authors:  Rikke Karlin Jepsen; Anne Guldhammer Skov; Birgit Guldhammer Skov
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

9.  Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status.

Authors:  DA-Ping Yu; Yu-Jie Dong; Hai-Qing Zhang; Jing-Hui Wang; Yang Qu; Li-Juan Zhou; Dan Su; Li-Li Zhang; Dan Zhao; Yi-Ran Cai
Journal:  Biomed Rep       Date:  2014-03-20

10.  Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.

Authors:  Josef Singer; Judit Fazekas; Wei Wang; Marlene Weichselbaumer; Miroslawa Matz; Alexander Mader; Willibald Steinfellner; Sarah Meitz; Diana Mechtcheriakova; Yuri Sobanov; Michael Willmann; Thomas Stockner; Edzard Spillner; Renate Kunert; Erika Jensen-Jarolim
Journal:  Mol Cancer Ther       Date:  2014-04-22       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.